Project Grant R01AI189319
Award Date
4/10/25
Completion Date
3/31/30
Dollars Obligated
$877K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) is funding a research study on the Kaposi's Sarcoma-associated Herpesvirus (KSHV) at the University of California, Davis. The $564,698 award will focus on understanding the role of the KSHV terminal repeat sequence in regulating the virus's lytic gene promoters, with the goal of identifying new drug targets to control KSHV replication and associated malignancies. The 5-year project aims to build...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University in the amount of $1,283,291 on June 14, 2024. The grant supports research to investigate how Kaposi's Sarcoma-Associated Herpesvirus (KSHV) alters host cell metabolism, specifically spermidine and proline synthesis, to promote latent viral infection and...
The federal Project Grant award of $1,368,755.00 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to define the functions of the Kaposi's Sarcoma-Associated Herpesvirus (KSHV) Latency-Associated Nuclear Antigen (LANA) in viral pathogenesis and immune evasion. The primary awardee, the University of Arkansas for Medical Sciences (UAMS), will leverage a chimeric murine gammaherpesvirus...
This Project Grant award from the National Cancer Institute under the Cancer Biology Research (CFDA 93.396) program provides $411,400 to Northwestern University to develop a primary human cell culture model that recapitulates the transformed features of Kaposi's sarcoma-associated herpesvirus (KSHV)-infected cells. The goal is to identify KSHV-induced genes that promote the loss of contact inhibition of proliferation, a hallmark of oncogenic transformation, in KSHV-infected lymphatic endothelial...
This Project Grant award of $1,638,000.00 from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), will fund a longitudinal study investigating the effects of the oral environment on reactivation and shedding of Kaposi's sarcoma-associated herpesvirus (KSHV) in Ugandan adults living with HIV. The study will enroll 600 participants across three groups - people living with HIV on long-term antiretroviral therapy, newly diagnosed ART-naive people living...
This R15 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will provide $430,285 over 3 years to researchers at Towson University in Maryland. The project aims to investigate the role of RTA-induced ubiquitination in Kaposi's Sarcoma-associated Herpesvirus (KSHV) latency and lytic replication, with the goal of identifying cellular targets and small molecule inhibitors for therapeutic...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $425,125 to Brigham & Women's Hospital Inc. to conduct research on understanding how Epstein-Barr virus (EBV) transformed B-cells evade natural killer (NK) cell surveillance. The research aims to characterize the role of protocadherin gamma proteins in enabling EBV+ lymphoma cells to resist NK cell-mediated lysis, as...
This $185,513 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to design and develop O'PROTACS-based degraders targeting the Kaposi's sarcoma-associated herpesvirus (KSHV) oncoprotein LANA. The goal is to interfere with the survival of KSHV-positive tumor cells both in vitro and in vivo, with the hope of developing new interventional strategies to improve outcomes for...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $768,976 Project Grant to Seattle Pacific University under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant, awarded on June 18, 2024, will fund research focused on understanding how the alteration of host cell metabolism by gammaherpesvirus infections, such as Epstein-Barr virus (EBV) and Kaposi's sarcoma herpesvirus (KSHV), contributes to viral replication and potentially cancer...
This Project Grant award under the National Institutes of Health's Allergy and Infectious Diseases Research program (CFDA 93.855) provides $3,471,592 to Brigham & Women's Hospital Inc. to conduct research on the immune selection of HIV-1 reservoir cells in human clinical trials. The research aims to identify specific immunological pathways and vulnerabilities of the HIV-1 reservoir cell pool that can be exploited in future interventions to limit HIV-1 persistence. The award period is from...